<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Mol Biol</journal-id><journal-id journal-id-type="iso-abbrev">J Mol Biol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of molecular biology</journal-title></journal-title-group><issn pub-type="ppub">0022-2836</issn><issn pub-type="epub">1089-8638</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12788883</article-id><article-id pub-id-type="pmcid-ver">PMC12788883.1</article-id><article-id pub-id-type="pmcaid">12788883</article-id><article-id pub-id-type="pmcaiid">12788883</article-id><article-id pub-id-type="manuscript-id">NIHMS2129375</article-id><article-id pub-id-type="pmid">40907939</article-id><article-id pub-id-type="doi">10.1016/j.jmb.2025.169414</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2129375</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2129375</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The tRNA Editing Complex ADAT2/3 Promotes Cancer Cell Growth and Codon-biased mRNA Translation<sup><xref rid="FN3" ref-type="fn">&#9734;</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ramirez-Moya</surname><given-names initials="J">Julia</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Antika</surname><given-names initials="TR">Titi Rindi</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Q">Qi</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiong</surname><given-names initials="X">Xushen</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ali</surname><given-names initials="R">Raja</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gutierrez</surname><given-names initials="A">Alejandro</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A8" ref-type="aff">8</xref><xref rid="A9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gregory</surname><given-names initials="RI">Richard I.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="A8" ref-type="aff">8</xref><xref rid="A10" ref-type="aff">10</xref></contrib></contrib-group><aff id="A1"><label>1</label>Stem Cell Program, Boston Children&#8217;s Hospital, Boston, MA 02115, USA</aff><aff id="A2"><label>2</label>Division of Hematology/Oncology, Boston Children&#8217;s Hospital, Boston, MA 02115, USA</aff><aff id="A3"><label>3</label>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA</aff><aff id="A4"><label>4</label>Molecular, Cell, and Cancer Biology Department, UMass Chan Medical School, Worcester, MA 01605, USA</aff><aff id="A5"><label>5</label>Rice Research Institute, Guangdong Academy of Agricultural Sciences, Guangzhou 510640 Guangdong Province, China</aff><aff id="A6"><label>6</label>Guangdong Key Laboratory of New Technology in Rice Breeding, Guangzhou 510640 Guangdong Province, China</aff><aff id="A7"><label>7</label>Zhejiang University Medical Center, Hangzhou, Zhejiang Province, China</aff><aff id="A8"><label>8</label>Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA</aff><aff id="A9"><label>9</label>Department of Oncology, St. Jude Children&#8217;s Research Hospital, Memphis, TN, USA</aff><aff id="A10"><label>10</label>Harvard Initiative for RNA Medicine, Boston, MA 02115, USA</aff><author-notes><corresp id="CR1"><bold><italic toggle="yes">Correspondence to Richard I. Gregory:</italic></bold> Stem Cell Program, Boston Children&#8217;s Hospital, Boston, MA 02115, USA. <email>richard.gregory1@umassmed.edu</email><italic toggle="yes">(R.I. Gregory)</italic></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>9</month><year>2025</year></pub-date><volume>437</volume><issue>21</issue><issue-id pub-id-type="pmc-issue-id">504676</issue-id><fpage>169414</fpage><lpage>169414</lpage><pub-history><event event-type="nihms-submitted"><date><day>02</day><month>01</month><year>2026</year></date></event><event event-type="pmc-release"><date><day>09</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>10</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-10 00:25:12.930"><day>10</day><month>01</month><year>2026</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecom-mons.org/licenses/by/4.0/">https://creativecom-mons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2129375.pdf"/><abstract id="ABS1"><p id="P1">Transfer RNAs (tRNAs) are subject to various chemical modifications that influence their stability or function. Adenosine to Inosine (A-to-I) editing in the tRNA anticodon at position A34 is an important modification that expands anticodon-codon recognition at the wobble position and is required for normal mRNA translation. The relevance of tRNA editing in cancer remains unexplored. Here we show that the genes encoding the ADAT2/3 deaminase complex, responsible for A-to-I tRNA editing in humans, are commonly amplified and/or overexpressed in several tumor types including liposarcoma (LPS). We find that LPS cell growth and tumorigenicity is dependent on ADAT2/3 tRNA editing activity. Mechanistically, we find decreased tRNA editing upon ADAT2 depletion, defective translation of a subset of mRNAs, and altered protein homeostasis. Thus, ADAT2 promotes oncogenesis and the translation of growth promoting mRNAs that are enriched in NNC codons that lack cognate tRNAs and therefore depend on A-I tRNA editing for decoding and mRNA translation. Our results identify ADAT2/3 as a potential new cancer therapeutic target.</p></abstract><kwd-group><kwd>Editing</kwd><kwd>Inosine</kwd><kwd>ADAT2</kwd><kwd>ADAT3</kwd><kwd>tRNA</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>Introduction</title><p id="P2">Transfer RNAs (tRNAs) are key adaptor molecules essential for messenger RNA (mRNA) translation and are subject to numerous posttranscriptional modifications, including Adenosine-to-Inosine (A-to-I) editing, the major RNA editing type that occurs in humans [<xref rid="R1" ref-type="bibr">1</xref>]. The enzyme responsible for this modification is the Adenosine Deaminase Acting on tRNA (ADAT) complex comprising the catalytic ADAT2 component and the ADAT3 co-factor that is essential for recognition and presentation of the tRNA to the ADAT2 catalytic pocket for editing the subset of human tRNAs with adenosine at position 34 (A34) [<xref rid="R2" ref-type="bibr">2</xref>&#8211;<xref rid="R6" ref-type="bibr">6</xref>]. tRNA nucleotide 34 is located within the anticodon, which faces the third base of mRNA codons during translation. Modification of A-to-I at this wobble position has an obvious implication for anticodon:codon recognition because, while A34 can base-pair with U, I34 is capable of pairing with A, U, and C (<xref rid="F1" ref-type="fig">Figure 1A</xref>). This expands the repertoire of triplets that the modified tRNA can recognize and, in doing so, profoundly modifies the balance between codon usage and tRNA availability. Although only tRNA-Arg-ACG is modified in most prokaryotes, up to eight tRNAs are inosine-modified in eukaryotes including tRNA-Ala-AGC, tRNA-Arg-ACG, tRNA-Ile-AAT, tRNA-Leu-AAG, tRNA-Pro-AGG, tRNA-Ser-AGA, tRNA-Thr-AGT and tRNA-Val-AAC [<xref rid="R2" ref-type="bibr">2</xref>]. In fact, eukaryotic ADAT emergence was accompanied by a dramatic genomic expansion of A34-tRNA genes, and most eukaryotic genomes lack tRNA genes that produce G34-tRNAs [<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>]. Therefore, A-to-I editing is required to compensate for the lack of G34-tRNAs otherwise needed to decode C-ending (NNC) codons [<xref rid="R9" ref-type="bibr">9</xref>]. Mutation in the Schizosaccharomyces pombe <italic toggle="yes">tad3</italic> gene (ortholog of the human <italic toggle="yes">ADAT3</italic> gene) causes diminished deaminase activity of the complex and results in defective cell cycle progression [<xref rid="R10" ref-type="bibr">10</xref>]. ADAT2 or ADAT3 knockdown in human HEK293T cells similarly leads to defects in cell cycle progression as well as cell adhesion phenotypes [<xref rid="R11" ref-type="bibr">11</xref>]. Germline mutations in <italic toggle="yes">ADAT3</italic> resulting in compromised A-I tRNA editing are associated with intellectual disability in human patients [<xref rid="R12" ref-type="bibr">12</xref>&#8211;<xref rid="R14" ref-type="bibr">14</xref>], and conditional <italic toggle="yes">Adat2</italic> deletion in the B-cell lineage causes a near complete loss of peripheral blood B-cells in mice [<xref rid="R15" ref-type="bibr">15</xref>].</p><p id="P3">Codon composition is an important factor that influences translation rates, and the clustering of codons in mRNAs that have a low level of cognate tRNAs limits the rate of translation [<xref rid="R16" ref-type="bibr">16</xref>]. Thus, the translation of genes rich in ADAT-sensitive codons (codons translated by I34-tRNAs) might benefit from the increased decoding capacity of inosine-modified tRNAs. In agreement with this prediction, self-renewing mouse and human embryonic stem cells (ESCs) that express many genes enriched in ADAT-sensitive codons display elevated I34 levels [<xref rid="R17" ref-type="bibr">17</xref>].</p><p id="P4">Here we explore for the first time the relevance of the A-to-I tRNA editing complex in cancer. Analysis of The Cancer Genome Atlas (TCGA) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.gov/tcga" ext-link-type="uri">https://www.cancer.gov/tcga</ext-link>), identified that the components of the ADAT complex are dysregulated in human tumors. We observed that sarcoma tumors, and specifically liposarcomas, are the cancer types that present the highest level of genetic amplification of the <italic toggle="yes">ADAT2</italic> and <italic toggle="yes">ADAT3</italic> loci. Liposarcoma (LPS) is a rare cancer that arises in fat cells, typically in the soft tissue of the body. There are several subtypes of liposarcoma, each with different clinical and pathological features. The most common subtype is well-differentiated liposarcoma, which is typically slow-growing and has a low propensity for metastasis. Other subtypes include myxoid liposarcoma, pleomorphic liposarcoma, and dedifferentiated liposarcoma, which are generally more aggressive and have a higher risk of spreading to other parts of the body [<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref>]. The primary treatment for liposarcoma is surgical removal of the tumor, with radiation therapy or chemotherapy used in some cases [<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref>]. However, some tumors present a high risk of metastasis and a poor prognosis, thereby highlighting the importance of identifying new molecular markers for better diagnosis and possible future therapeutic targets.</p><p id="P5">Here we demonstrate that the ADAT2/3 complex has an oncogenic role in LPS. We show that ADAT2 promotes the translation of oncogenic mRNAs that are enriched in ADAT-dependent codons, providing a selective advantage to cancer cells. Our data provide new insights into the role of the ADAT complex in gene expression and cancer and we propose that the ADAT2/3 deaminase could represent a new therapeutic target for cancer treatment.</p></sec><sec id="S2"><title>Results</title><sec id="S3"><title>ADAT2 and ADAT3 are amplified and overexpressed in human tumors</title><p id="P6">To explore the possible altered mRNA expression levels of ADAT2 and ADAT3 in cancer we analyzed available RNA-Seq data from The Cancer Genome Atlas (TCGA) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.gov/tcga" ext-link-type="uri">https://www.cancer.gov/tcga</ext-link>). This revealed elevated ADAT2 and ADAT3 mRNA expression levels in most types of human tumors compared to corresponding normal tissues (<xref rid="F1" ref-type="fig">Figure 1B</xref>, <xref rid="SD1" ref-type="supplementary-material">Figure S1A</xref>&#8211;<xref rid="SD1" ref-type="supplementary-material">B</xref>). Moreover, gene copy number analysis showed that <italic toggle="yes">ADAT2</italic> and <italic toggle="yes">ADAT3</italic> loci are frequently amplified in several tumor types (<xref rid="F1" ref-type="fig">Figure 1C</xref>, <xref rid="SD1" ref-type="supplementary-material">Figure S2</xref>). Taken together, the cancer genetics and mRNA expression data implicate ADAT2 and ADAT3 in various cancers. More detailed examination of TCGA datasets revealed that ADAT2 and ADAT3 mRNA expression is elevated in sarcomas compared with normal tissue samples (<xref rid="F1" ref-type="fig">Figure 1B</xref>). Among the sarcoma group, frequent amplification of <italic toggle="yes">ADAT2</italic> and <italic toggle="yes">ADAT3</italic> genes is observed in the dedifferentiated liposarcoma (LPS) subset (<xref rid="F1" ref-type="fig">Figure 1C</xref>, <xref rid="SD1" ref-type="supplementary-material">Figure S2</xref>). Therefore, we considered LPS a relevant model in which to study the role of ADAT proteins in cancer and to explore the underlying molecular mechanisms.</p></sec><sec id="S4"><title>ADAT2 and ADAT3 are required for cancer cell growth and tumorigenicity</title><p id="P7">To explore the requirement for ADAT2/3 in cancer cells, we used short harpin RNA (shRNA) constructs to specifically knock down ADAT2 and ADAT3 expression in human LPS cell lines. We used two different shRNAs in two LPS cell lines with different amplification levels of ADAT2 and ADAT3. According to our results, the LPS853 cell line harbors nine copies of <italic toggle="yes">ADAT2</italic> and four copies of <italic toggle="yes">ADAT3</italic> (<xref rid="F1" ref-type="fig">Figure 1D</xref>). Considering this, we used LPS853 as a model LPS cell line with <italic toggle="yes">ADAT2/3</italic> gene amplification and the LPS6 cell line as a non-amplified LPS cell line (<xref rid="F1" ref-type="fig">Figure 1D</xref>). These two cellular models allowed us to examine the requirement of ADAT2/3 in human LPS cell lines and to furthermore determine if the cells with a higher amplification and/or expression of ADAT2/3 are more sensitive to its silencing.</p><p id="P8">We evaluated the effects of ADAT2 depletion on cancer cell growth and viability using a panel of cellular assays to measure several hallmarks of cancer and comparing our knockdown LPS cells to the parental cell line or cells transduced with a non-targeting shRNA (shGFP) as controls (<xref rid="SD1" ref-type="supplementary-material">Figure S3</xref>). We observed that depletion of ADAT2 caused decreased cell proliferation (<xref rid="F2" ref-type="fig">Figure 2A</xref>), colony formation (<xref rid="F2" ref-type="fig">Figure 2B</xref>), invasion (<xref rid="F2" ref-type="fig">Figure 2C</xref>), and anchorage-independent cell growth (<xref rid="F2" ref-type="fig">Figure 2D</xref>). Interestingly, we found that ADAT2-amplified LPS853 cells are more sensitive to ADAT-depletion than non-amplified LPS6 cells. Moreover, in contrast to the LPS cancer cell lines, knockdown of ADAT2 in the non-cancerous human BJ fibroblasts did not cause any strong growth defects (<xref rid="SD1" ref-type="supplementary-material">Figure S4A</xref>&#8211;<xref rid="SD1" ref-type="supplementary-material">B</xref>). These results suggest that ADAT2 promotes cancer cell growth and is essential for maintaining a malignant phenotype in LPS cell lines. To further explore this hypothesis, we assessed the ability of the stable ADAT2 KD cell lines to form tumors <italic toggle="yes">in vivo</italic> in immunocompromised mice. These <italic toggle="yes">in vivo</italic> experiments were performed using LPS853 cells since the strongest cellular phenotypes were observed in this cell line upon ADAT2 depletion (<xref rid="F2" ref-type="fig">Figure 2A</xref>&#8211;<xref rid="F2" ref-type="fig">D</xref>) and LPS853 cells grow faster than LPS6 cells in monolayer culture conditions (<xref rid="F2" ref-type="fig">Figure 2A</xref>) and display more robust colony formation in anchorage-independent growth assays (<xref rid="F2" ref-type="fig">Figure 2D</xref>). Strikingly, we observed that silencing of this enzyme strongly suppressed the ability of these cells to form tumors in these xenograft studies (<xref rid="F2" ref-type="fig">Figure 2E</xref>). These results highlight ADAT2 as a possible new therapeutic target in cancer. Very similar results were observed upon ADAT3 silencing (<xref rid="SD1" ref-type="supplementary-material">Figure S5A</xref>, <xref rid="SD1" ref-type="supplementary-material">B</xref>), with ADAT3-depleted LPS cells showing decreased proliferation (<xref rid="SD1" ref-type="supplementary-material">Figure S5C</xref>), colony formation (<xref rid="SD1" ref-type="supplementary-material">Figure S5D</xref>), invasion (<xref rid="SD1" ref-type="supplementary-material">Figure S5E</xref>), and anchorage-independent cell growth (<xref rid="SD1" ref-type="supplementary-material">Figure S5F</xref>), which is consistent with the ADAT3 subunit being required for tRNA editing activity of the ADAT2/3 complex. As such, ADAT3 might also be also considered as a potential anti-cancer therapeutic target.</p></sec><sec id="S5"><title>ADAT2 catalytic activity promotes growth of liposarcoma cells</title><p id="P9">To ensure that the growth phenotypes observed in LPS cells are due specifically to ADAT2 deficiency and to rule out possible off-target effects of the shRNA, we performed rescue assays in which an ADAT2 overexpression vector was introduced into the ADAT2 KD cells (<xref rid="F3" ref-type="fig">Figure 3A</xref>&#8211;<xref rid="F3" ref-type="fig">B</xref>) For this purpose, we generated an overexpression vector containing the coding sequence of ADAT2 and we performed directed mutagenesis to introduce silent mutations within the open reading frame (ORF) to avoid the specific silencing by the ADAT2 shRNA previously employed. We repeated the above-mentioned functional assays to compare the KD cells to the rescued ADAT2 in the shADAT2 condition and the control shGFP cells. Our results showed that the observed phenotypes are specific for the ADAT2 KD, as the recovery of ADAT2 expression rescues the proliferation, invasion, and soft agar colony formation capability in both LPS853 and LPS6 cell lines (<xref rid="F3" ref-type="fig">Figure 3C</xref>&#8211;<xref rid="F3" ref-type="fig">E</xref>). In addition, we also studied the importance of ADAT2 tRNA editing activity by including a catalytic mutant version of ADAT2 (ADAT2 E73A) [<xref rid="R2" ref-type="bibr">2</xref>] in our rescue experiments. Our results showed that only the wild-type ADAT2 and not the catalytically inactive mutant form is able to rescue the malignant phenotype (<xref rid="F3" ref-type="fig">Figure 3C</xref>&#8211;<xref rid="F3" ref-type="fig">E</xref>), thereby strongly supporting that the tRNA-editing activity of ADAT2 is responsible for the observed cancer cell growth phenotypes.</p></sec><sec id="S6"><title>Decreased A-to-I tRNA editing in ADAT2-depleted LPS cells</title><p id="P10">To investigate the molecular mechanism involved in the oncogenic role of the ADAT2/3 complex, we first performed small RNA sequencing in the LPS853 control and ADAT2-knockdown cells and measured A-to-I tRNA editing levels. Inosine is resolved as guanosine upon cDNA sequencing. Consistent with the previous report on HEK239T cells [<xref rid="R22" ref-type="bibr">22</xref>], the proportion of inosine at position 34 is reduced by up to ~4-fold in several tRNA isodecoder families including tRNA-Ser-AGA, tRNA-Val-AAC, tRNA-Pro-AGG, and tRNA-Thr-AGT (<xref rid="F4" ref-type="fig">Figure 4A</xref>). Other tRNAs including tRNA-Arg-ACG and tRNA-Ile-AAT, although belonging to tRNA isodecoder families that are edited [<xref rid="R23" ref-type="bibr">23</xref>], were largely unaffected by knockdown of ADAT2. ADAT2 depletion had no effect on the steady-state levels of edited tRNAs (<xref rid="F4" ref-type="fig">Figure 4B</xref>). Our results show an overall decrease in the editing of several tRNA families with some more affected than others under conditions of partial ADAT2 depletion in LPS cells.</p></sec><sec id="S7"><title>ADAT2 deficiency leads to codon-biased changes in mRNA translation</title><p id="P11">To examine the impact of ADAT2 silencing and decreased A-to-I tRNA editing on mRNA translation, we performed ribosome footprinting (Ribo-Seq) experiments in control and ADAT2-depleted LPS853 cells. Ribo-Seq revealed a remodeling of the mRNA &#8216;translatome&#8217; due to ADAT2-deficiency with 183 mRNAs &gt; 1.5-fold more efficiently translated (upregulated) and 146 mRNAs less efficiently translated (downregulated) in ADAT2-knockdown compared with control cells (<xref rid="F5" ref-type="fig">Figure 5A</xref>, <xref rid="F5" ref-type="fig">B</xref>, and <xref rid="SD2" ref-type="supplementary-material">Supplementary Dataset 1</xref>). Interestingly, gene ontology (GO) analysis showed that the genes with decreased translation efficiency in ADAT2-depleted cells are enriched in cancer-related processes including cell migration, cell proliferation, and cell motility (<xref rid="F5" ref-type="fig">Figure 5C</xref>). These molecular changes in the translation efficiency of growth-promoting genes likely help explain the oncogenic role of ADAT2 and the cellular growth phenotypes we observed ADAT2-depleted LPS cells (<xref rid="F2" ref-type="fig">Figure 2</xref>, <xref rid="F3" ref-type="fig">Figure 3</xref>). We next explored whether the mRNAs with altered translation in ADAT2-depleted cells are enriched in codons that are normally decoded by the subset of A-to-I edited tRNAs. For this purpose, we compared the codon usage between genes with increased translation efficiency (TE up) versus decreased translation efficiency (TE down) with the enrichment of codons in the TE Down subset compared with the global average codon usage across all human open reading frames (ORFs) throughout the genome. We found that several ADAT-sensitive codons are both enriched in mRNAs with decreased versus increased TE and are enriched in the TE down group compared with global average codon usage (<xref rid="F5" ref-type="fig">Figure 5D</xref>). A significant enrichment of multiple ADAT-sensitive codons including GCC, CCC, CCA, ACC, CGC, GTC, ATC, and CGA in the mRNAs with decreased translation efficiency (TE down) upon ADAT2-knockdown was observed (<xref rid="F5" ref-type="fig">Figure 5D</xref>). Interestingly, we found NNC codons to be the most dependent on A-to-I tRNA editing, which correlates with the general absence of G34 tRNAs in the human genome [<xref rid="R9" ref-type="bibr">9</xref>]. Therefore, decoding of NNC is dependent on A-I editing since these codons would otherwise lack cognate tRNAs for translation. Amongst this group are Arg-CGC, Pro-CCC, Ala-GCC, and Thr-ACC codons that are all significantly enriched in the mRNAs with decreased translation due to ADAT2 deficiency (<xref rid="F5" ref-type="fig">Figure 5E</xref>). Conversely, NNT codons that can be decoded by both the unedited (A34) as well as by the edited tRNAs including CTT, ATT, GTT, and GCT codons have a lower dependance on tRNA editing and are thus less enriched in the mRNAs with decreased translation efficiency in the ADAT2-depleted cells (<xref rid="F5" ref-type="fig">Figure 5D</xref>). Interestingly, the highly enriched NNC codons (GTC, CCC, and ACC) are recognized by the edited form of tRNA-Val-AAC, tRNA-Pro-AGG and tRNA-Thr-AGT, respectively, further supporting the importance of ADAT2/3-mediated editing of this subset of tRNAs for efficient translation of mRNAs containing these codons. In conclusion, ADAT2-deficiency causes selectively decreased translation of mRNAs that are enriched in NNC codons that depend on A-I tRNA editing for decoding. Thus, ADAT2-mediated tRNA editing is required for codon-biased mRNA translation of growth-promoting genes in human cancer cells.</p></sec><sec id="S8"><title>ADAT2 knockdown impairs translation, alters the proteome, and promotes protein aggregation</title><p id="P12">To assess the impact of ADAT2 deficiency on global protein synthesis, we performed a metabolic labeling assay and observed a significant reduction in S<sup>35</sup>-methionine incorporation in ADAT2-silenced cells (<xref rid="F6" ref-type="fig">Figure 6A</xref>), indicating impaired translational output. We then hypothesized that tRNA editing dysregulation may affect translation by altering the codon-anticodon pairing specificity of the tRNA. This alteration can potentially lead to changes in the expression of specific proteins that may be beneficial for cancer cells, explaining the importance of tRNA editing in cancer biology and the role of the ADAT complex as an oncogene in liposarcoma. To test our hypothesis, we analyzed protein expression in ADAT2-silenced and control LPS853 cells using quantitative proteomics. We identified 241 proteins that were upregulated and 240 that were downregulated in response to ADAT2 silencing (<xref rid="F6" ref-type="fig">Figure 6B</xref>, and <xref rid="SD3" ref-type="supplementary-material">Supplementary Dataset 2</xref>). Notably, many of the downregulated proteins are associated with key oncogenic processes, including DNA replication, lipid biosynthesis, mitosis, cell division, and cell cycle progression (<xref rid="F6" ref-type="fig">Figure 6C</xref>). Further analysis revealed that ADAT-sensitive codons are enriched in proteins with decreased expression, both when comparing decreased versus increased groups and when comparing the decreased group to global codon usage averages (<xref rid="F6" ref-type="fig">Figure 6D</xref>). Considering that altered translational dynamics can impact the co-translational folding of nascent polypeptides, we next explored the possibility that ADAT2 deficiency might lead to protein misfolding/aggregation. Indeed, we found strongly increased protein aggregation (aggresomes) in ADAT2-depleted cells (<xref rid="F6" ref-type="fig">Figure 6E</xref>), suggesting that reduced codon optimality and translational stress may lead to protein misfolding and aggregation.</p></sec></sec><sec id="S9"><title>Discussion</title><p id="P13">This study showed that the ADAT2/3 genes encoding the A-to-I tRNA editing complex are commonly amplified and/or overexpressed in cancer, and that ADAT2/3-depletion inhibits cancer cell growth hallmarks and tumorigenicity in human Liposarcoma cell lines. tRNA sequencing revealed decreased A-I editing of ANN tRNAs in ADAT2-deficient cells. It is worth mentioning that some tRNAs are more susceptible to ADAT knockdown than others likely reflecting the incomplete loss of ADAT2 editing activity in these LPS cells. Notably, Ribo-Seq revealed decreased translation of a set of mRNAs that are enriched in codons that depend on A-I editing for decoding. Thus, ADAT2 is required for tRNA editing and it promotes oncogenesis by enhancing the translation of growth promoting genes that are enriched in NNC codons that lack cognate tRNAs and therefore require A-I tRNA editing for expression.</p><p id="P14">Although this study focused on human Liposarcoma, it is likely that the identified oncogenic function of ADAT2/3 is applicable to a broad range of different cancer types. Inspection of the DepMap dataset (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://depmap.org/portal" ext-link-type="uri">https://depmap.org/portal</ext-link>) identified many different cancer cell lines that require ADAT2/3 for proliferation, in particular Rhabdomyosarcoma (ADAT2) and Diffuse Large B-cell Lymphoma (ADAT3) [<xref rid="R24" ref-type="bibr">24</xref>]. In further support of this widespread oncogenic role, a previous study found that ADAT2-depletion led to decreased proliferation of HeLa (cervical carcinoma) and HT-29 (colorectal carcinoma) cells [<xref rid="R11" ref-type="bibr">11</xref>]. Moreover, increased ADAT2 mRNA level is associated with poor prognosis in breast cancer patients and ADAT protein levels were found by immunohistochemistry staining to be higher in BRCA1 mutant compared with BRCA1 wild-type breast tumors [<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref>]. Taken together with our findings that ADAT2 and ADAT3 mRNA expression levels are elevated in most tumor types compared with the corresponding normal tissues we propose that ADAT2/3 is broadly relevant in cancer.</p><p id="P15">Our findings reported here add to the growing list of tRNA-modifying enzymes with important roles in cancer [<xref rid="R27" ref-type="bibr">27</xref>]. For example, other modifications in the anticodon [<xref rid="R28" ref-type="bibr">28</xref>], anticodon loop [<xref rid="R29" ref-type="bibr">29</xref>], as well as in the body of the tRNA can impact tRNA function and/or abundance [<xref rid="R30" ref-type="bibr">30</xref>&#8211;<xref rid="R36" ref-type="bibr">36</xref>]. Interestingly, the growth promoting and oncogenic influence of these different tRNA modifications converge mechanistically at the level of codon-biased mRNA translation whereby subsets of mRNAs linked to several different hallmarks of cancer including cell-cycle genes are enriched in certain codons and can therefore be coordinately controlled at the mRNA translational level through changes in the modification status of the corresponding tRNAs that are preferentially required for decoding these mRNA subsets [<xref rid="R37" ref-type="bibr">37</xref>,<xref rid="R38" ref-type="bibr">38</xref>].</p><p id="P16">Enzymes involved in maintaining the epitranscriptome are emerging as promising new targets for cancer therapy [<xref rid="R39" ref-type="bibr">39</xref>,<xref rid="R40" ref-type="bibr">40</xref>]. Pharmacological inhibition of the m<sup>6</sup>A methyltransferase (MTase) METTL3, represents a promising strategy for treating acute myeloid leukemia (AML) and likely other cancer types [<xref rid="R41" ref-type="bibr">41</xref>]. Our results uncover an oncogenic role of ADAT2/3 and identify this adenosine deaminase as a possible new pharmacologically tractable target for cancer therapy. The available crystal structures of the ADAT2/3 complex [<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref>] as well as cryo-EM structures of the ADAT2/3 heterodimer bound to its substrate tRNA [<xref rid="R5" ref-type="bibr">5</xref>] should facilitate the development of small molecules inhibitors of this enzyme.</p></sec><sec id="S10"><title>Materials and Methods</title><sec id="S11"><title>Cell lines</title><p id="P17">BJ human fibroblasts and HEK293T cells were purchased from ATCC. LPS6 [<xref rid="R42" ref-type="bibr">42</xref>] was a gift from Eric Snyder, LPS141 [<xref rid="R42" ref-type="bibr">42</xref>] and LPS853 [<xref rid="R43" ref-type="bibr">43</xref>] were gifts from Jonathan Fletcher, and 93T449 [<xref rid="R44" ref-type="bibr">44</xref>] was a gift from Florence Pedeutour. BJ and HEK293T were cultured in DMEM supplemented with 10% FBS and 1X penicillin/streptomycin. LPS141 and 93T449 cells were cultured in RPMI 1640 medium supplemented with 15% FBS and 1&#215; penicillin/streptomycin. LPS853 cells were cultured in IMDM medium supplemented with 15% FBS and 1&#215; penicillin/streptomycin. LP6 cells were cultured in DMEM/F12 medium supplemented with 10% FBS, 1% Glutamax and 1&#215; penicillin/streptomycin. All cell lines were cultured in the presence of 5% CO2 at 37 &#176;C.</p></sec><sec id="S12"><title>Plasmid Construction and shRNAs</title><p id="P18">For overexpression experiments, the ADAT2 and ADAT3 full-length cDNAs were cloned in the pBabe-puro vector using BamHI and SalI restriction sites. A Flag-tag was added in the N-terminal region for both proteins. Mutant ADAT2 E73A was produced by directed mutagenesis using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs). Mutagenesis primers are detailed in <xref rid="SD1" ref-type="supplementary-material">Table S1</xref>. For the ADAT2 rescue experiments, wild-type ADAT2, and the catalytic mutant (E73A) form were mutated to avoid shRNA silencing using the primers detailed in <xref rid="SD1" ref-type="supplementary-material">Table S1</xref> and using the same directed mutagenesis kit. For knockdown experiments, shADAT2 #1 (#653), shADAT2 #4 (#656), shADAT3 #4 (#576) and shADAT3 #5 (#577) were purchased from Sigma Aldrich.</p></sec><sec id="S13"><title>Copy number analysis</title><p id="P19">Genomic DNA was isolated using Quick-DNA microprep kit (Zymo) following the manufacturer&#8217;s instructions. ADAT2 and ADAT3 copy number alteration was evaluated using gene specific TaqMan Copy Number Assay (Thermo Fisher Scientific) according to the manufacturer&#8217;s instructions.</p></sec><sec id="S14"><title>Quantitative RT-PCR</title><p id="P20">For gene expression analysis, total RNA was isolated with Trizol Reagent (Invitrogen). Template cDNA synthesis was performed using the SuperScript III Reverse Transcriptase (Invitrogen). The levels of specific RNAs were measured by quantitative reverse transcription-PCR (qRT-PCR) using the StepOne real-time PCR machines and the Fast SybrGreen PCR mastermix (ThermoFisher, 4385612) according to the manufacturer&#8217;s instructions. All samples, including the template controls, were assayed in triplicate. The relative number of target transcripts was normalized to GAPDH or ACTIN. The relative quantification of target gene expression was performed with the standard curve or comparative cycle threshold (CT) method. All primers were purchased from Genewiz and are described in <xref rid="SD1" ref-type="supplementary-material">Table S1</xref>.</p></sec><sec id="S15"><title>Protein extraction and western blotting</title><p id="P21">Cells were lysed and proteins extracted with Passive Lysis Buffer (Promega) according to the manufacturer&#8217;s instructions. Protein concentration was measured using the Bradford method (Bio-Rad Laboratories). Samples were separated by sodium dodecyl sulfate&#8211; polyacrylamide gel electrophoresis (SDS-PAGE) Novex 4&#8211;20% Tris-Glycine gel (Thermo Fisher Scientific) and transferred to nitrocellulose membranes (Bio-Rad). Immunoreactive proteins were visualized by enhanced chemiluminescence (Thermo Fisher Scientific). The ADAT2 (ab135429), ADAT3 (ab247133), and Tubulin (ab6064) antibodies were obtained from Abcam. The Vinculin antibody (sc-73614) was purchased from Santa Cruz and &#946;-Actin (8H10D10) (#3700) from Cell Signaling.</p></sec><sec id="S16"><title>Virus production and generation of stable knockdown and overexpression cells</title><p id="P22">Generation of stable knockdown and overexpression cells via virus transduction was performed described previously [<xref rid="R45" ref-type="bibr">45</xref>]. For knockdown experiments, the procedure involved co-transfecting shRNA-containing pLKO.1 vectors with pLP1, pLP2, and VSVG into HEK293T cells. For overexpression, Gag-Pol and VSVG plasmids were co-transfected with pBabe vectors containing either wild-type ADAT2, wild-type ADAT3, ADAT2 catalytic dead mutant (ADAT2 E73A), or an empty vector as a control. The viruses were collected at 48 h and 72 h after transfection and used to infect cells. Infected cells were selected using puromycin (2.5 &#956;g/mL) added to the culture medium 48 hr after infection. shRNA-expressing BJ fibroblast cells were maintained in medium supplemented with puromycin (2.5 &#956;g/mL).</p></sec><sec id="S17"><title>Proliferation and cell viability assays</title><p id="P23">Cell proliferation/cell viability was measured using the XTT metabolic assay (Cyman Chemical) and 2D colony formation using crystal violet staining. For XTT analysis, either 500 or 1,000 cells were seeded in 96-well plates and allowed to grow for 72 h, after which dye reduction was recorded on a spectrophotometer at 450 nm. Crystal violet staining was performed by seeding 1,000 or 2,000 cells in each well of a 6-well plate. After 2&#8211;3 weeks, individual wells were fixed in 4% paraformaldehyde and stained with crystal violet. Pictures were obtained after extensive washing and drying, and the staining reagent was resolubilized in 1% acetic acid and quantified at 590 nm as an indirect measure of cell number.</p></sec><sec id="S18"><title>Invasion assay</title><p id="P24">Cell invasion was assayed in FluoroBlok cell culture inserts (Corning) coated on the upper side with Matrigel (Corning) mixed with DMEM at a final concentration of 300 &#956;g/mL. 75,000 LPS853, cells or 50,000 LPS6 cells in DMEM containing 0.2% FBS were seeded in the upper chamber and 10% FBS was added to the bottom chamber as a chemoattractant. Cells were allowed to invade for 22 h at 37 &#176;C, 5% CO<sub>2</sub> atmosphere. Cells were fixed in 100% methanol and stained with a 300 nM DAPI solution. Images were obtained using a florescence microscope and cells counted using Image J.</p></sec><sec id="S19"><title>Soft agar colony formation assays</title><p id="P25">5,000 LPS853 or LPS6 cells were mixed with 0.35% top-agar (SeaPlaque, Lonza) and were plated onto 0.7% base-agar (SeaPlaque, Lonza) in six-well plates. Three weeks (LPS853) or five weeks (LPS6) after plating the cells into soft agar, the plates were stained with violet crystal and imaged using a EVOS FL auto plate imager (Thermo Fisher Scientific) at 2x (LPS853) or 4x (LPS6). Colony numbers were counted using image J.</p></sec><sec id="S20"><title><italic toggle="yes">In vivo</italic> studies</title><p id="P26">Female NU/J (Nude) immunodeficient mice (Jackson Laboratory) aged 4&#8211;6 weeks were used for subcutaneous injections to investigate the role of ADAT2 in tumor formation. For this purpose, 5 &#215; 10<sup>5</sup> LPS853 cells with stable knockdown of ADAT2 (shADAT2 #1 and #4) or a negative control (shGFP) were used. The indicated number of cells were mixed with serum-free medium and growth factor reduced Matrigel (Corning) (1:1) and injected into the right flank of 6&#8211;8 mice for each condition. Tumor growth was monitored twice a week using calipers. The tumor volume was calculated using the formula 1/2(length &#215; width<sup>2</sup>). End-point tumors were collected and photographed.</p></sec><sec id="S21"><title>Small RNA sequencing</title><p id="P27">To analyze the tRNA levels and editing, small RNA sequencing was performed. Total RNA was isolated with Trizol Reagent (Invitrogen) and treated with recombinant AlkB and AlkB D135S for demethylation for 2 h as detailed in [<xref rid="R46" ref-type="bibr">46</xref>]. Demethylated small RNA was purified using the RNA Clean and Concentrator &#8722;5 kit (Zymo Research) and the library prepared using the NEBnext Multiplex small RNA library prep for Illumina (New England Biolabs) following the manufacturer&#8217;s instructions. Amplified libraries were selected and purified by gel-extraction on 6% native TBE gels (Thermo Fisher Scientific). Libraries were sequenced with Illumina NextSeq 500 and tRNA sequencing reads were filtered and analyzed as described [<xref rid="R22" ref-type="bibr">22</xref>]. The tRNA-seq clean reads were mapped against human tRNA sequences using Bowtie with a maximum of two mismatches and no more than 50 multiple mappings. Sequence reads mapping to pre-tRNAs (i.e. reads including 5&#8242; leader-, 3&#8242; trailer-, and/or intronic sequences) were excluded. Then, Samtools was used to identify the A to G mutations at the 34 location (I34) of tRNAs. The A-to-I editing rate was calculated as the mutation ratio of G allele in this location.</p></sec><sec id="S22"><title>Ribosome footprinting (Ribo-seq)</title><p id="P28">LPS853 cells stably silenced for ADAT2 (shADAT2), or control shRNA (shGFP) were grown to 80&#8211;90% confluence to obtain at least 50 million cells per condition and replicate (<italic toggle="yes">n</italic> = 2). Ribosome footprinting was performed according to TruSeq<sup>&#174;</sup> Ribo Profile system (Illumina) with some modifications described in [<xref rid="R30" ref-type="bibr">30</xref>]. For library preparation the NEBNext Multiplex Small RNA Library Prep set for Illumina (New England Biolabs) was used. In parallel, total RNA input samples were isolated, and fragmented and the library obtained using the TruSeq stranded total RNA Kit (Illumina). Amplified libraries were selected and purified by gel-extraction on 6% native TBE gels (Thermo Fisher Scientific). Libraries were sequenced with Illumina NovaSeq SE50. To perform the analysis, the sequences of both input and Ribo-seq samples were processed to obtain clean reads by trimming the adapters and filtering out low-quality sequences. For the Ribo-seq input data, the clean reads were aligned to reference genome sequences using STAR [<xref rid="R47" ref-type="bibr">47</xref>], resulting in BAM mapping files. HTSeq [<xref rid="R48" ref-type="bibr">48</xref>] was then used to calculate the read counts for each gene from GENCODE gene mode. For the cleaned Ribo-seq data, ribosome-protected fragments (RPFs) were collapsed into FASTA format using fq2collapedFa. Codon occupancy analysis and translation efficiency analysis were performed using RiboToolkit (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bioinformatics.caf.ac.cn/RiboToolkit_demo" ext-link-type="uri">https://bioinformatics.caf.ac.cn/RiboToolkit_demo</ext-link>) [<xref rid="R49" ref-type="bibr">49</xref>]. Translation efficiency was calculated by dividing RPF abundance on CDS by its mRNA abundance of input sample. Differential translation genes were defined by a <italic toggle="yes">p</italic>-value &lt;0.05 and a 1.5-fold change (<xref rid="SD2" ref-type="supplementary-material">Supplementary Dataset 1</xref>).</p></sec><sec id="S23"><title>Proteomic analysis by stable isotope labeling using amino acids in cell culture (SILAC)</title><p id="P29">LPS853 cells were grown in media supplemented with isotopic-labeled <sup>13</sup>C<sub>6</sub>
<sup>15</sup>N<sub>2</sub> l-lysine and <sup>13</sup>C<sub>6</sub>
<sup>15</sup>N<sup>4</sup> l-arginine (heavy) or normal amino acids (light) until a labeling efficiency &gt;95% was achieved following the instructions of the SILAC Protein Quantitation Kit (Trypsin) &#8211; DMEM (A33972, Thermo Scientific). Light SILAC-labeled control LPS853 as well as heavy-labeled shADAT2 LPS853 cells were lysed in 1x passive cell lysis buffer (Promega) supplemented with complete protease inhibitor (11873580001, Roche). Protein lysates were cleared by centrifugation at 14,000<italic toggle="yes">g</italic> for 5 min at 4 C. Equal amounts of heavy and light protein (1:1) amounts were mixed with 2&#215; reducing sample buffer and 100 &#956;g of clarified sample was separated by SDS-PAGE (4&#8211;20%). Three technical replicates were performed for each sample. Mass Spectrometry was performed by the Taplin Mass spectrometry core facility using a LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher Scientific, San Jose, CA). SILAC protein ratios (H/L) were determined as the average of all peptide ratios assigned to a protein between heavy and light samples. Differential protein expression was defined as adjusted <italic toggle="yes">p</italic>-value &lt;0.05 and log<sub>2</sub> fold-change &#177;0.5 (<xref rid="SD3" ref-type="supplementary-material">Supplementary Dataset 2</xref>).</p></sec><sec id="S24"><title>Metabolic labeling of newly synthesized proteins</title><p id="P30">Global protein synthesis was measured using S35-methionine incorporation. LPS853 cells were incubated in methionine-free medium, followed by pulse labeling with S35-methionine. LPS853 cell incubated with Cycloheximide (CHX) served as a positive control. Control- (shGFP) and ADAT2-depleted (shADAT2) cells were lysed, and equal protein amounts were separated by SDS-PAGE and transferred to nitrocellulose membranes. Radiolabeled proteins were detected by autoradiography and quantified by densitometry.</p></sec><sec id="S25"><title>Protein aggregation assay</title><p id="P31">Protein aggregation was assessed by immunofluorescence using an Aggresome Detection Kit (Abcam ab139486). Cells were fixed with 4% paraformaldehyde, permeabilized and incubated with aggresome detection reagent. MG-132 serves as a positive control. The Immunofluorescence images of the cells containing aggregates were acquired using a confocal microscope and quantified by using Fiji and AggreCount.</p></sec><sec id="S26"><title>Functional annotation of candidate genes</title><p id="P32">The genes obtained after the Ribo-seq (genes with up- or down- translation efficiency) and proteomics (up- and down-regulated genes) were processed by The Database for Annotation, Visualization and Integrated Discovery (DAVID) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://david.ncifcrf.gov/" ext-link-type="uri">https://david.ncifcrf.gov</ext-link>) for functional annotation.</p></sec><sec id="S27"><title>TCGA data analysis</title><p id="P33">To study the frequency of genomic alterations in samples from the TGCA the cBioportal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cbioportal.org/" ext-link-type="uri">https://www.cbioportal.org</ext-link>) was used. The mRNA expression levels were obtained from Firebrowse (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.firebrowse.org/" ext-link-type="uri">https://www.firebrowse.org</ext-link>).</p></sec><sec id="S28"><title>Statistical analysis</title><p id="P34">Quantification and statistical analysis methods were described in individual method sections and Figure legends. Results are expressed as the mean &#177; standard deviation of three different experiments (<italic toggle="yes">n</italic> = 3) unless specified. Statistical significance was determined by Student&#8217;s <italic toggle="yes">t</italic>-test analysis (two-tailed) and differences were considered significant at a <italic toggle="yes">p</italic>-value &lt;0.05.</p></sec><sec id="S29"><title>Code availability</title><p id="P35">The software and algorithms for data analyses used in this study are all well-established from previous work and are referenced throughout the manuscript.</p></sec><sec id="S30"><title>Statistics and reproducibility</title><p id="P36">Detailed statistical analysis methods and sample numbers (<italic toggle="yes">n</italic>) were described in individual figure legends. GraphPad Prism and Microsoft Excel were used for data presentation. Paired or unpaired two-tailed Student <italic toggle="yes">t</italic>-tests, Fisher&#8217;s exact tests, or Mann-Whitney two-sided U tests were used for two comparisons. Statistical significance is considered for all analysis where *<italic toggle="yes">p</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes">p</italic> &lt; 0.01, <sup>***</sup><italic toggle="yes">p</italic> &lt; 0.001, <sup>****</sup><italic toggle="yes">p</italic> &lt; 0.0001.</p></sec></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>Supplementary data 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2129375-supplement-Supplementary_data_1.docx" id="d67e827" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD2" position="float" content-type="local-data" orientation="portrait"><label>supplementary dataset 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2129375-supplement-supplementary_dataset_1.xls" id="d67e830" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD3" position="float" content-type="local-data" orientation="portrait"><label>supplementary dataset 2</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS2129375-supplement-supplementary_dataset_2.xlsx" id="d67e833" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack id="S31"><title>Acknowledgments</title><p id="P37">R.I.G. was supported by an Outstanding Investigator Award (R35CA232115) from the National Cancer Institute (NCI) of the NIH. We thank the Taplin Mass Spectrometry Facility, Harvard Medical School, for help with the SILAC proteomics analysis.</p></ack><fn-group><fn fn-type="COI-statement" id="FN1"><p id="P40">DECLARATION OF COMPETING INTEREST</p><p id="P41">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: &#8216;R.I.G. is a co-founder, scientific advisory board member, and equity holder of Redona Therapeutics (formerly 28/7 Therapeutics), and advisor to Alida Biosciences, and to O<sub>2</sub>nix Bio. The Gregory lab has received research funding from Sanofi, Astellas, and Ono. All other authors declare no competing interests.&#8217;.</p></fn><fn id="FN2"><p id="P42">CRediT authorship contribution statement</p><p id="P43"><bold>Julia Ramirez-Moya:</bold> Writing &#8211; original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. <bold>Titi Rindi Antika:</bold> Writing &#8211; review &amp; editing, Formal analysis, Data curation. <bold>Qi Liu:</bold> Methodology, Formal analysis, Data curation. <bold>Xushen Xiong:</bold> Formal analysis, Data curation. <bold>Raja Ali:</bold> Methodology, Investigation, Formal analysis. <bold>Alejandro Gutierrez:</bold> Supervision, Project administration, Funding acquisition, Formal analysis, Conceptualization. <bold>Richard I. Gregory:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Supervision, Project administration, Funding acquisition, Formal analysis, Data curation, Conceptualization.</p></fn><fn id="FN3"><label>&#9734;</label><p id="P44">This article is part of a special issue entitled: &#8216;tRNA modifications (2025)&#8217; published in Journal of Molecular Biology.</p></fn></fn-group><sec sec-type="data-availability" id="S32"><title>DATA AVAILABILITY</title><p id="P38">High-throughput sequencing data have been deposited in the Gene Expression Omnibus (GEO) under the accession numbers GSE234132 (tRNA-seq) and GEO Pending (Ribo-seq).</p></sec><app-group><app id="APP1"><label>Appendix A.</label><title>Supplementary material</title><p id="P39">Supplementary material to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1016/j.jmb.2025.169414" ext-link-type="uri">https://doi.org/10.1016/j.jmb.2025.169414</ext-link>.</p></app></app-group><ref-list><title>References</title><ref id="R1"><label>[1].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Torres</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Batlle</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ribas de Pouplana</surname><given-names>L</given-names></name>, (<year>2014</year>). <article-title>Role of tRNA modifications in human diseases</article-title>. <source>Trends Mol. Med</source>. <volume>20</volume>, <fpage>306</fpage>&#8211;<lpage>314</lpage>.<pub-id pub-id-type="pmid">24581449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2014.01.008</pub-id></mixed-citation></ref><ref id="R2"><label>[2].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Torres</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Pineyro</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Filonava</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Stracker</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Batlle</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ribas de Pouplana</surname><given-names>L</given-names></name>, (<year>2014</year>). <article-title>A-to-I editing on tRNAs: biochemical, biological and evolutionary implications</article-title>. <source>FEBS Letters</source><volume>588</volume>, <fpage>4279</fpage>&#8211;<lpage>4286</lpage>.<pub-id pub-id-type="pmid">25263703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.febslet.2014.09.025</pub-id></mixed-citation></ref><ref id="R3"><label>[3].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name>, <etal/>, (<year>2020</year>). <article-title>Crystal structure of the yeast heterodimeric ADAT2/3 deaminase</article-title>. <source>BMC Biol</source>. <volume>18</volume>, <fpage>189</fpage>.<pub-id pub-id-type="pmid">33272269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12915-020-00920-2</pub-id><pub-id pub-id-type="pmcid">PMC7713142</pub-id></mixed-citation></ref><ref id="R4"><label>[4].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ramos-Morales</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bayam</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Del-Pozo-Rodriguez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Salinas-Giege</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Marek</surname><given-names>M</given-names></name>, <etal/>, (<year>2021</year>). <article-title>The structure of the mouse ADAT2/ADAT3 complex reveals the molecular basis for mammalian tRNA wobble adenosine-to-inosine deamination</article-title>. <source>Nucleic Acids Res</source>. <volume>49</volume>, <fpage>6529</fpage>&#8211;<lpage>6548</lpage>.<pub-id pub-id-type="pmid">34057470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkab436</pub-id><pub-id pub-id-type="pmcid">PMC8216470</pub-id></mixed-citation></ref><ref id="R5"><label>[5].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dolce</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Zimmer</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Tengo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Weis</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Rubio</surname><given-names>MAT</given-names></name>,<etal/>,(<year>2022</year>).<article-title>Structural basis for sequence-independent substrate selection by eukaryotic wobble base tRNA deaminase ADAT2/3</article-title>. <source>Nature Commun</source>. <volume>13</volume>, <fpage>6737</fpage>.<pub-id pub-id-type="pmid">36347890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-34441-z</pub-id><pub-id pub-id-type="pmcid">PMC9643335</pub-id></mixed-citation></ref><ref id="R6"><label>[6].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gerber</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Keller</surname><given-names>W</given-names></name>, (<year>1999</year>). <article-title>An adenosine deaminase that generates inosine at the wobble position of tRNAs</article-title>. <source>Science</source><volume>286</volume>, <fpage>1146</fpage>&#8211;<lpage>1149</lpage>.<pub-id pub-id-type="pmid">10550050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.286.5442.1146</pub-id></mixed-citation></ref><ref id="R7"><label>[7].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rafels-Ybern</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Torres</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Camacho</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Herencia-Ropero</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Roura Frigole</surname><given-names>H</given-names></name>, <etal/>, (<year>2019</year>). <article-title>The expansion of inosine at the wobble position of tRNAs, and its role in the evolution of proteomes</article-title>. <source>Mol. Biol. Evol</source>. <volume>36</volume>, <fpage>650</fpage>&#8211;<lpage>662</lpage>.<pub-id pub-id-type="pmid">30590541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/molbev/msy245</pub-id></mixed-citation></ref><ref id="R8"><label>[8].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chan</surname><given-names>PP</given-names></name>, <name name-style="western"><surname>Lowe</surname><given-names>TM</given-names></name>, (<year>2016</year>). <article-title>GtRNAdb 2.0: an expanded database of transfer RNA genes identified in complete and draft genomes</article-title>. <source>Nucleic Acids Res</source>. <volume>44</volume>, <fpage>184</fpage>&#8211;<lpage>189</lpage>.</mixed-citation></ref><ref id="R9"><label>[9].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Srinivasan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Torres</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Ribas de Pouplana</surname><given-names>L</given-names></name>, (<year>2021</year>). <article-title>Inosine in biology and disease</article-title>. <source>Genes (Basel)</source>, <volume>12</volume>.</mixed-citation></ref><ref id="R10"><label>[10].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tsutsumi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sugiura</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tokuoka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ohta</surname><given-names>K</given-names></name>, (<year>2007</year>). <article-title>Wobble inosine tRNA modification is essential to cell cycle progression in G(1)/S and G(2)/M transitions in fission yeast</article-title>. <source>J. Biol. Chem</source>. <volume>282</volume>, <fpage>33459</fpage>&#8211;<lpage>33465</lpage>.<pub-id pub-id-type="pmid">17875641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M706869200</pub-id></mixed-citation></ref><ref id="R11"><label>[11].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Torres</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Rodriguez-Escriba</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Marcet-Houben</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Santos Vieira</surname><given-names>HG</given-names></name>, <name name-style="western"><surname>Camacho</surname><given-names>N</given-names></name>, (<year>2021</year>). <article-title>Human tRNAs with inosine 34 are essential to efficiently translate eukarya-specific low-complexity proteins</article-title>. <source>Nucleic Acids Res</source>. <volume>49</volume>, <fpage>7011</fpage>&#8211;<lpage>7034</lpage>.<pub-id pub-id-type="pmid">34125917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkab461</pub-id><pub-id pub-id-type="pmcid">PMC8266599</pub-id></mixed-citation></ref><ref id="R12"><label>[12].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Alazami</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Hijazi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Al-Dosari</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Shaheen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hashem</surname><given-names>A</given-names></name>, <etal/>, (<year>2013</year>). <article-title>Mutation in ADAT3, encoding adenosine deaminase acting on transfer RNA, causes intellectual disability and strabismus</article-title>. <source>J. Med. Genet</source>. <volume>50</volume>, <fpage>425</fpage>&#8211;<lpage>430</lpage>.<pub-id pub-id-type="pmid">23620220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmedgenet-2012-101378</pub-id></mixed-citation></ref><ref id="R13"><label>[13].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ramos</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hagelskamp</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Kellner</surname><given-names>SM</given-names></name>, <etal/>, (<year>2019</year>). <article-title>Formation of tRNA wobble inosine in humans is disrupted by a millennia-old mutation causing intellectual disability</article-title>. <source>Mol. Cell Biol</source>, <volume>39</volume>.</mixed-citation></ref><ref id="R14"><label>[14].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ramos</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Proven</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Halvardson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hagelskamp</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Kuchinskaya</surname><given-names>E</given-names></name>, <etal/>, (<year>2020</year>). <article-title>Identification and rescue of a tRNA wobble inosine deficiency causing intellectual disability disorder</article-title>. <source>RNA</source><volume>26</volume>, <fpage>1654</fpage>&#8211;<lpage>1666</lpage>.<pub-id pub-id-type="pmid">32763916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1261/rna.076380.120</pub-id><pub-id pub-id-type="pmcid">PMC7566568</pub-id></mixed-citation></ref><ref id="R15"><label>[15].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gigu&#232;re</surname><given-names>S</given-names></name><etal/>, (<year>2024</year>). <article-title>Antibody production relies on the tRNA inosine wobble modification to meet biased codon demand</article-title>. <source>Science</source><volume>383</volume>, <fpage>205</fpage>&#8211;<lpage>211</lpage>.<pub-id pub-id-type="pmid">38207021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.adi1763</pub-id><pub-id pub-id-type="pmcid">PMC10954030</pub-id></mixed-citation></ref><ref id="R16"><label>[16].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Parmley</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Huynen</surname><given-names>MA</given-names></name>, (<year>2009</year>). <article-title>Clustering of codons with rare cognate tRNAs in human genes suggests an extra level of expression regulation</article-title>. <source>PLoS Genet</source>. <volume>5</volume>, <fpage>1000548</fpage>.</mixed-citation></ref><ref id="R17"><label>[17].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bornel&#246;v</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Selmi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Flad</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dietmann</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Frye</surname><given-names>M</given-names></name>, (<year>2019</year>). <article-title>Codon usage optimization in pluripotent embryonic stem cells</article-title>. <source>Genome Biol</source>. <volume>20</volume>, <fpage>119</fpage>.<pub-id pub-id-type="pmid">31174582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-019-1726-z</pub-id><pub-id pub-id-type="pmcid">PMC6555954</pub-id></mixed-citation></ref><ref id="R18"><label>[18].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lahat</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Anaya</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Tuvin</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lev</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Pollock</surname><given-names>RE</given-names></name>, (<year>2008</year>). <article-title>Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches</article-title>. <source>Ann. Surg. Oncol</source>. <volume>15</volume>, <fpage>1585</fpage>&#8211;<lpage>1593</lpage>.<pub-id pub-id-type="pmid">18398663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-007-9805-x</pub-id></mixed-citation></ref><ref id="R19"><label>[19].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gutierrez</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Perez</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Franceschi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Moffat</surname><given-names>FL</given-names></name>, <name name-style="western"><surname>Livingstone</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Koniaris</surname><given-names>LG</given-names></name>, (<year>2007</year>). <article-title>Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry</article-title>. <source>J. Surg. Res</source>. <volume>141</volume>, <fpage>105</fpage>&#8211;<lpage>114</lpage>.<pub-id pub-id-type="pmid">17512548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jss.2007.02.026</pub-id></mixed-citation></ref><ref id="R20"><label>[20].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Eilber</surname><given-names>FC</given-names></name>, <name name-style="western"><surname>Eilber</surname><given-names>FR</given-names></name>, <name name-style="western"><surname>Eckardt</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rosen</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Riedel</surname><given-names>E</given-names></name>, <etal/>, (<year>2004</year>). <article-title>The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma</article-title>. <source>Ann. Surg</source>. <volume>240</volume>, <fpage>686</fpage>&#8211;<lpage>695</lpage>.<pub-id pub-id-type="pmid">15383796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.sla.0000141710.74073.0d</pub-id><pub-id pub-id-type="pmcid">PMC1356470</pub-id></mixed-citation></ref><ref id="R21"><label>[21].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Singer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Antonescu</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Riedel</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Brennan</surname><given-names>MF</given-names></name>, (<year>2003</year>). <article-title>Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma</article-title>. <source>Ann. Surg</source>. <volume>238</volume>, <fpage>358</fpage>&#8211;<lpage>370</lpage>.<pub-id pub-id-type="pmid">14501502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.sla.0000086542.11899.38</pub-id><pub-id pub-id-type="pmcid">PMC1422708</pub-id></mixed-citation></ref><ref id="R22"><label>[22].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Torres</surname><given-names>AG</given-names></name><etal/>, (<year>2015</year>). <article-title>Inosine modifications in human tRNAs are incorporated at the precursor tRNA level</article-title>. <source>Nucleic Acids Res</source>. <volume>43</volume> (<issue>10</issue>), <fpage>5145</fpage>&#8211;<lpage>5157</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv277</pub-id>.<pub-id pub-id-type="pmid">25916855</pub-id><pub-id pub-id-type="pmcid">PMC4446420</pub-id></mixed-citation></ref><ref id="R23"><label>[23].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jukes</surname><given-names>TH</given-names></name>, (<year>1973</year>). <article-title>Possibilities for the evolution of the genetic code from a preceding form</article-title>. <source>Nature</source><volume>246</volume> (<issue>5427</issue>), <fpage>22</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1038/246022a0</pub-id>.<pub-id pub-id-type="pmid">4585842</pub-id></mixed-citation></ref><ref id="R24"><label>[24].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tsherniak</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vazquez</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Montgomery</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Weir</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Kryukov</surname><given-names>G</given-names></name>, <etal/>, (<year>2017</year>). <article-title>Defining a cancer dependency map</article-title>. <source>Cell</source><volume>170</volume>, <fpage>564</fpage>&#8211;<lpage>576</lpage>.<pub-id pub-id-type="pmid">28753430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.06.010</pub-id><pub-id pub-id-type="pmcid">PMC5667678</pub-id></mixed-citation></ref><ref id="R25"><label>[25].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Berthel</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Vincent</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Eberst</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Torres</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Dacheux</surname><given-names>E</given-names></name>, <etal/>, (<year>2020</year>). <article-title>Uncovering the translational regulatory activity of the tumor suppressor BRCA1</article-title>. <source>Cells</source>, <volume>9</volume>.</mixed-citation></ref><ref id="R26"><label>[26].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zuo</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>X</given-names></name>, <etal/>, (<year>2024</year>). <article-title>Genome-wide identification and analysis of epithelial-mesenchymal transition-related RNA-binding proteins and alternative splicing in a human breast cancer cell line</article-title>. <source>Sci. Rep</source>. <volume>14</volume>, <fpage>11753</fpage>.<pub-id pub-id-type="pmid">38783078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-62681-0</pub-id><pub-id pub-id-type="pmcid">PMC11116388</pub-id></mixed-citation></ref><ref id="R27"><label>[27].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name>, (<year>2021</year>). <article-title>The expanding world of tRNA modifications and their disease relevance</article-title>. <source>Nature Rev. Mol. Cell Biol</source>. <volume>22</volume> (<issue>6</issue>), <fpage>375</fpage>&#8211;<lpage>392</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-021-00342-0</pub-id>.<pub-id pub-id-type="pmid">33658722</pub-id></mixed-citation></ref><ref id="R28"><label>[28].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rapino</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Delaunay</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rambow</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Tharun</surname><given-names>L</given-names></name>,<etal/>,(<year>2018</year>).<article-title>Codon-specific translation reprogramming promotes resistance to targeted therapy</article-title>. <source>Nature</source><volume>558</volume>, <fpage>605</fpage>&#8211;<lpage>609</lpage>.<pub-id pub-id-type="pmid">29925953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-018-0243-7</pub-id></mixed-citation></ref><ref id="R29"><label>[29].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cui</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sendinc</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Gregory</surname><given-names>RI</given-names></name>, (<year>2024</year>). <article-title>m(3)C32 tRNA modification controls serine codon-biased mRNA translation, cell cycle, and DNA-damage response</article-title>. <source>Nature Commun</source>. <volume>15</volume>, <fpage>5775</fpage>.<pub-id pub-id-type="pmid">38982125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-50161-y</pub-id><pub-id pub-id-type="pmcid">PMC11233606</pub-id></mixed-citation></ref><ref id="R30"><label>[30].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Orellana</surname><given-names>EA</given-names></name><etal/>, (<year>2021</year>). <article-title>METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation</article-title>. <source>Mol. Cell</source><volume>81</volume> (<issue>16</issue>), <fpage>3323</fpage>&#8211;<lpage>3338.e14</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2021.06.031</pub-id>.<pub-id pub-id-type="pmid">34352207</pub-id><pub-id pub-id-type="pmcid">PMC8380730</pub-id></mixed-citation></ref><ref id="R31"><label>[31].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dai</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>X</given-names></name>, <etal/>, (<year>2021</year>). <article-title>N(7)-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression</article-title>. <source>Mol. Cell</source><volume>81</volume>, <fpage>3339</fpage>&#8211;<lpage>3355</lpage>.<pub-id pub-id-type="pmid">34352206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2021.07.003</pub-id></mixed-citation></ref><ref id="R32"><label>[32].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ying</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C</given-names></name>, <etal/>, (<year>2021</year>). <article-title>METTL1-m(7) G-EGFR/EFEMP1 axis promotes the bladder cancer development</article-title>. <source>Clin. Transl. Med</source>. <volume>11</volume>, <fpage>675</fpage>.</mixed-citation></ref><ref id="R33"><label>[33].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name>, <etal/>, (<year>2021</year>).<article-title>METTL1/WDR4-mediated m(7)G tRNA modifications and m(7)G codon usage promote mRNA translation and lung cancer progression</article-title>. <source>Mol. Ther</source>. <volume>29</volume>, <fpage>3422</fpage>&#8211;<lpage>3435</lpage>.<pub-id pub-id-type="pmid">34371184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2021.08.005</pub-id><pub-id pub-id-type="pmcid">PMC8636169</pub-id></mixed-citation></ref><ref id="R34"><label>[34].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>J</given-names></name>, <etal/>, (<year>2021</year>). <article-title>METTL1 promotes hepatocarcinogenesis via m(7) G tRNA modification-dependent translation control</article-title>. <source>Clin. Transl. Med</source>. <volume>11</volume>, <fpage>661</fpage>.</mixed-citation></ref><ref id="R35"><label>[35].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Zou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>H</given-names></name>, <etal/>, (<year>2023</year>). <article-title>METTL1/WDR4-mediated tRNA m(7)G modification and mRNA translation control promote oncogenesis and doxorubicin resistance</article-title>. <source>Oncogene</source><volume>42</volume>, <fpage>1900</fpage>&#8211;<lpage>1912</lpage>.<pub-id pub-id-type="pmid">37185458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41388-023-02695-6</pub-id></mixed-citation></ref><ref id="R36"><label>[36].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>P</given-names></name>, <etal/>, (<year>2022</year>).<article-title>N(7)-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT/beta-catenin pathway in nasopharyngeal carcinoma</article-title>. <source>Oncogene</source><volume>41</volume>, <fpage>2239</fpage>&#8211;<lpage>2253</lpage>.<pub-id pub-id-type="pmid">35217794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41388-022-02250-9</pub-id></mixed-citation></ref><ref id="R37"><label>[37].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Orellana</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Siegal</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Gregory</surname><given-names>RI</given-names></name>, (<year>2022</year>). <article-title>tRNA dysregulation and disease</article-title>. <source>Nature Rev. Genet</source>. <volume>23</volume>, <fpage>651</fpage>&#8211;<lpage>664</lpage>.<pub-id pub-id-type="pmid">35681060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41576-022-00501-9</pub-id><pub-id pub-id-type="pmcid">PMC11170316</pub-id></mixed-citation></ref><ref id="R38"><label>[38].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dedon</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Begley</surname><given-names>TJ</given-names></name>, (<year>2022</year>). <article-title>Dysfunctional tRNA reprogramming and codon-biased translation in cancer</article-title>. <source>Trends Mol. Med</source>. <volume>28</volume>, <fpage>964</fpage>&#8211;<lpage>978</lpage>.<pub-id pub-id-type="pmid">36241532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2022.09.007</pub-id><pub-id pub-id-type="pmcid">PMC10071289</pub-id></mixed-citation></ref><ref id="R39"><label>[39].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pomaville</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>He</surname><given-names>C</given-names></name>, (<year>2023</year>). <article-title>Advances in targeting RNA modifications for anticancer therapy</article-title>. <source>Trends Cancer</source><volume>9</volume>, <fpage>528</fpage>&#8211;<lpage>542</lpage>.<pub-id pub-id-type="pmid">37147166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trecan.2023.04.003</pub-id><pub-id pub-id-type="pmcid">PMC10330282</pub-id></mixed-citation></ref><ref id="R40"><label>[40].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>A&#241;azco-Guenkova</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Miguel-L&#243;pez</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Monteagudo-Garc&#237;a</surname><given-names>&#211;</given-names></name>, <name name-style="western"><surname>Garc&#237;a-V&#237;lchez</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Blanco</surname><given-names>S</given-names></name>, (<year>2024</year>). <article-title>The impact of tRNA modifications on translation in cancer: identifying novel therapeutic avenues</article-title>. <source>NAR Cancer</source><volume>6</volume>, (<issue>1</issue>) <fpage>zcae012</fpage><pub-id pub-id-type="doi">10.1093/narcan/zcae012</pub-id>.<pub-id pub-id-type="pmid">38476632</pub-id><pub-id pub-id-type="pmcid">PMC10928989</pub-id></mixed-citation></ref><ref id="R41"><label>[41].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yankova</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Blackaby</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Albertella</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rak</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Braekeleer</surname><given-names>E</given-names></name>, <etal/>, (<year>2021</year>). <article-title>Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia</article-title>. <source>Nature</source>.</mixed-citation></ref><ref id="R42"><label>[42].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Snyder</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Sandstrom</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Law</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fiore</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sicinska</surname><given-names>E</given-names></name>, <etal/>, (<year>2009</year>). <article-title>c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme</article-title>. <source>J. Pathol</source>. <volume>218</volume>, <fpage>292</fpage>&#8211;<lpage>300</lpage>.<pub-id pub-id-type="pmid">19449367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.2564</pub-id></mixed-citation></ref><ref id="R43"><label>[43].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ou</surname><given-names>WB</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Eilers</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Kuang</surname><given-names>Y</given-names></name>, <etal/>, (<year>2015</year>). <article-title>HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status</article-title>. <source>Oncotarget</source><volume>6</volume>, <fpage>10510</fpage>&#8211;<lpage>10520</lpage>.<pub-id pub-id-type="pmid">25888633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.3230</pub-id><pub-id pub-id-type="pmcid">PMC4496371</pub-id></mixed-citation></ref><ref id="R44"><label>[44].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pedeutour</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Forus</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Coindre</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Berner</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Nicolo</surname><given-names>G</given-names></name>, <etal/>, (<year>1999</year>). <article-title>Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors</article-title>. <source>Genes Chromosomes Cancer</source><volume>24</volume>, <fpage>30</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">9892106</pub-id></mixed-citation></ref><ref id="R45"><label>[45].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Choe</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Triboulet</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gregory</surname><given-names>RI</given-names></name>, (<year>2016</year>). <article-title>The m(6)A methyltransferase METTL3 promotes translation in human cancer cells</article-title>. <source>Mol. Cell</source><volume>62</volume>, <fpage>335</fpage>&#8211;<lpage>345</lpage>.<pub-id pub-id-type="pmid">27117702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2016.03.021</pub-id><pub-id pub-id-type="pmcid">PMC4860043</pub-id></mixed-citation></ref><ref id="R46"><label>[46].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>YZ</given-names></name>, <name name-style="western"><surname>Gregory</surname><given-names>RI</given-names></name>, (<year>2019</year>). <article-title>Nucleotide resolution profiling of m(7)G tRNA modification by TRAC-Seq</article-title>. <source>Nature Protoc</source>. <volume>14</volume>, <fpage>3220</fpage>&#8211;<lpage>3242</lpage>.<pub-id pub-id-type="pmid">31619810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41596-019-0226-7</pub-id><pub-id pub-id-type="pmcid">PMC8959837</pub-id></mixed-citation></ref><ref id="R47"><label>[47].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dobin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Schlesinger</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Drenkow</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zaleski</surname><given-names>C</given-names></name>, <etal/>, (<year>2013</year>). <article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source><volume>29</volume>, <fpage>15</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">23104886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmcid">PMC3530905</pub-id></mixed-citation></ref><ref id="R48"><label>[48].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Anders</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pyl</surname><given-names>PT</given-names></name>, <name name-style="western"><surname>Huber</surname><given-names>W</given-names></name>, (<year>2015</year>). <article-title>HTSeq&#8211;a Python framework to work with high-throughput sequencing data</article-title>. <source>Bioinformatics</source><volume>31</volume>, <fpage>166</fpage>&#8211;<lpage>169</lpage>.<pub-id pub-id-type="pmid">25260700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btu638</pub-id><pub-id pub-id-type="pmcid">PMC4287950</pub-id></mixed-citation></ref><ref id="R49"><label>[49].</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Shvarts</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sliz</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gregory</surname><given-names>RI</given-names></name>, (<year>2020</year>). <article-title>RiboToolkit: an integrated platform for analysis and annotation of ribosome profiling data to decode mRNA translation at codon resolution</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic>.&lt;</source>/References&gt;</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><title><italic toggle="yes">ADAT2/3</italic> are amplified and overexpressed in liposarcoma tumors.</title><p id="P45">(<bold>A</bold>) Schematic representation of A-to-I tRNA editing and its role in codon recognition. (<bold>B</bold>) ADAT2 (left) and ADAT3 (right) mRNA levels in sarcoma tumors and corresponding normal samples from the TCGA database. (<bold>C</bold>) <italic toggle="yes">ADAT2</italic> genetic alterations (mutations, amplifications, and deletions) in TCGA tumors. &#8216;Other sarcomas&#8217; refers to Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma. (<bold>D</bold>) <italic toggle="yes">ADAT2</italic> and <italic toggle="yes">ADAT3</italic> copy number in the indicated liposarcoma cell lines. <italic toggle="yes">p</italic>-values were from Wilcoxon Test, *<italic toggle="yes">p</italic> &lt; 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2129375-f0001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><title>ADAT2 is required for liposarcoma cell growth and tumorigenicity.</title><p id="P46">ADAT2-knockdown in human liposarcoma (LPS) cell lines, LPS853 and LPS6, cells using two different shRNAs [shADAT2 number 1 (shADAT2 #1) and shADAT2 number 4 (shADAT2 #4)]. shGFP and wild-type cells were used as negative controls. (<bold>A</bold>) Proliferation assay (<italic toggle="yes">n</italic> = 3). (<bold>B</bold>) 2D colony formation assay. Quantification (left) and representative images (right) (<italic toggle="yes">n</italic> = 3). (<bold>C</bold>) Invasion assay. Quantification (left) and representative images (right) (<italic toggle="yes">n</italic> = 3). (<bold>D</bold>) 3D soft agar colony formation assay. Quantification (left) and representative images (right) (<italic toggle="yes">n</italic> = 3). (<bold>E</bold>) Tumor growth in mouse xenografts using LPS853 cells. Quantification (left) and tumor images at endpoint (right). Error bars indicate standard deviations. Asterisks denote statistical significance assessed with Student&#8217;s <italic toggle="yes">t</italic>-test (two-tailed). *<italic toggle="yes">p</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes">p</italic> &lt; 0.01, <sup>***</sup><italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2129375-f0002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><title>ADAT2 catalytic activity promotes liposarcoma cell growth.</title><p id="P47">LPS853 and LPS6 cells were transduced with an ADAT2 shRNA (shADAT2) or with shGFP as a control. Then, ADAT2 wild-type or the catalytic mutant ADAT2 E73A were overexpressed to perform rescue assays. (<bold>A</bold>) Relative ADAT2 mRNA levels assayed by qPCR (<italic toggle="yes">n</italic> = 3). (<bold>B</bold>) Representative Western Blotting for ADAT2 protein. Vinculin (VINC) was used as loading control. (<bold>C</bold>) Proliferation assay (<italic toggle="yes">n</italic> = 3). (<bold>D</bold>) Invasion assay. Quantification (left) and representative images (right) (<italic toggle="yes">n</italic> = 3). (<bold>E</bold>) 3D soft agar colony formation assay (<italic toggle="yes">n</italic> = 3). Error bars indicate standard deviations. Asterisks denote statistical significance assessed with Student&#8217;s <italic toggle="yes">t</italic>-test (two-tailed). *<italic toggle="yes">p</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes">p</italic> &lt; 0.01, <sup>***</sup><italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2129375-f0003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><title>ADAT2-knockdown decreases A-to-I tRNA editing in liposarcoma cells.</title><p id="P48">(<bold>A</bold>) Relative proportion of inosine at position 34 in human ANN tRNAs observed in shGFP and shADAT2 LPS853 liposarcoma (LPS) cells (<italic toggle="yes">n</italic> = 3), with <sup>**</sup><italic toggle="yes">p</italic> &lt; 0.01, Wilcoxon Test. (<bold>B</bold>) Steady state tRNA expression levels in control versus ADAT2-depleted cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2129375-f0004.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><title>ADAT2 is required for translation of mRNAs enriched in ADAT-sensitive codons.</title><p id="P49">Ribo-seq was performed in shGFP and shADAT2 LPS853 cells (<italic toggle="yes">n</italic> = 2). (<bold>A</bold>) Translation efficiency (TE) change v.s. gene expression changes (red: up-translation, green: down-translation). TE was calculated by dividing the ribosome-protected fragments (RPF) signals by the input RNA-seq signals. (<bold>B</bold>) Translation changes observed after ADAT2 silencing (<italic toggle="yes">p</italic> &lt; 0.05, FC 1.5). (<bold>C</bold>) Gene ontology analysis of the TE downregulated and upregulated genes upon ADAT2 silencing (<italic toggle="yes">p</italic> &lt; 0.04, gene count &gt; 14). (<bold>D</bold>) Scatterplot of codon usage changes in the differentially translated genes in ADAT2 silenced cells. Codon usages were first calculated using RiboToolkit. Then, correlation analysis of codon usage changes in ADAT2 knockdown cells was performed by comparing translationally up-regulated genes against down-regulated genes and all other genes (Down vs Up and Down vs All other). ADAT-sensitive codons appear in blue. Dots in blue indicate ADAT-sensitive codons (codons read by ADAT-edited tRNAs). (<bold>E</bold>) The codon frequency information of human genes was downloaded from RiboToolkit. Statistical analysis of differential CGC, CCC, GCC and ACC codon usage among Translation efficiency (TE) up-regulated, down-regulated and unchanged genes was performed and shown in the boxplots. <italic toggle="yes">p</italic>-values were from wilcoxon Test, <sup>***</sup><italic toggle="yes">p</italic> &lt; 0.001; <sup>**</sup><italic toggle="yes">p</italic> &lt; 0.01; *<italic toggle="yes">p</italic> &lt; 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2129375-f0005.jpg"/></fig><fig position="float" id="F6" orientation="portrait"><label>Figure 6.</label><caption><title>ADAT2 knockdown impairs translation, alters the proteome, and promotes protein aggregation.</title><p id="P50">(<bold>A</bold>) Metabolic labeling shows reduced S<sup>35</sup>-methionine incorporation in ADAT2-silenced cells, indicating impaired global protein synthesis. CHX is Cycloheximide positive control. *<italic toggle="yes">p</italic> &lt; 0.05, ns = non-significant. (<bold>B</bold>) Quantitative SILAC-based proteomics analysis showing the number of proteins significantly upregulated (<italic toggle="yes">n</italic> = 241) and downregulated (<italic toggle="yes">n</italic> = 240) in ADAT2-silenced (heavy labeled) versus control (light-labeled) LPS853 cells. As a cutoff for up- and down-regulated proteins, we used log<sub>2</sub>(Fold Change) &#8805; &#177;0.5 and <italic toggle="yes">p</italic>-value &#8804;0.05 (<italic toggle="yes">n</italic> = 3, moderated <italic toggle="yes">t</italic>-test). <bold>(C</bold>) Gene ontology (GO) enrichment analysis of downregulated and upregulated proteins. (<bold>D</bold>) Codon usage analysis. The correlation analysis of codon usage changes in ADAT2 knockdown cells was performed by comparing up-regulated proteins against down-regulated proteins and all other genes (Down vs Up and Down vs All other). ADAT-sensitive codons appear in blue. (<bold>E</bold>) Immunofluorescence detection of aggregated proteins reveals increased protein aggregation in ADAT2-silenced LPS853 cells. Upper panel shows representative images with quantitation below. Cells incubated with the proteosome inhibitor MG-132 serves as a positive control. Shown is the mean &#177; SD number of aggregates per cell from <italic toggle="yes">n</italic> = 3 biological replicates. <italic toggle="yes">p</italic>-values were from one-way ANOVA test. <sup>**</sup><italic toggle="yes">p</italic> &lt; 0.01; *<italic toggle="yes">p</italic> &lt; 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-2129375-f0006.jpg"/></fig></floats-group></article></pmc-articleset>